In an elderly patient with bullous pemphigoid who developed confusion on prednisone 25 mg daily, is tapering to 20 mg daily for one week then to 15 mg daily too rapid?

Rapid Taper is Appropriate and Necessary Given Steroid-Induced Confusion

In an elderly patient with bullous pemphigoid who developed confusion on prednisolone 25mg, reducing to 20mg for one week then 15mg is not too rapid—in fact, this taper is appropriate and should be implemented immediately to minimize further neuropsychiatric complications while maintaining disease control.

Rationale for Rapid Dose Reduction

The development of confusion represents a serious steroid-induced adverse effect that significantly impacts quality of life and mortality risk in elderly patients. The current dose of 25mg is already relatively low for bullous pemphigoid treatment, and established guidelines support more aggressive initial tapering schedules once disease control is achieved 1.

Standard Tapering Guidelines Support This Approach

British Association of Dermatologists guidelines explicitly recommend reducing prednisolone by one-third to one-quarter at fortnightly intervals down to 15mg daily once disease control is achieved 1. Your proposed taper (25mg → 20mg → 15mg over 2 weeks) represents approximately a 20% reduction per week, which falls well within these evidence-based parameters.

The European Dermatology Forum consensus similarly states that dose reduction should begin 15 days after disease control, with earlier reduction being possible 2. Given that confusion has developed, earlier and more decisive tapering is medically justified to prevent further cognitive deterioration.

Critical Safety Considerations in Elderly Patients

Systemic corticosteroids carry significantly increased mortality risk in elderly BP patients compared to topical alternatives 3. The confusion you're observing is a red flag for serious steroid toxicity. Recent large-scale data demonstrates:

• Increased all-cause mortality with systemic steroids (HR 1.43) 3
• Increased risk of major adverse cardiac events (HR 1.33) 3
• Increased infection risk (HR 1.33) 3

These risks are dose-dependent and cumulative 1, making rapid dose reduction imperative when adverse effects emerge.

Disease Control vs. Steroid Toxicity Balance

While there is a slightly increased relapse risk with faster tapering (HR 0.85 for continued disease with systemic steroids) 3, this must be weighed against the immediate harm of ongoing confusion and long-term mortality risk. The FDA labeling emphasizes that dosage adjustments are necessary when patients experience adverse effects, and that "constant monitoring is needed in regard to drug dosage" 4.

Monitoring for Relapse During Taper

Define relapse as: new blisters, eczematous lesions, urticarial plaques >10cm diameter not healing within 1 week, or extension of established lesions 2. If relapse occurs during your taper, return to the previous effective dose (likely 20mg), not back to 25mg where confusion developed.

Practical Implementation Strategy

1. Reduce to 20mg daily immediately - administer in morning before 9am to minimize HPA axis suppression 4
2. After 7 days at 20mg, if no new blistering activity and confusion improving, reduce to 15mg daily
3. Monitor closely for new lesions during this 2-week period
4. If confusion persists at 15mg, consider adding steroid-sparing agents (azathioprine, doxycycline/nicotinamide) rather than maintaining higher steroid doses 1, 5

Alternative Considerations if Disease Flares

Should disease activity increase during taper, consider:

• Topical clobetasol propionate 10-20g daily as adjunctive therapy rather than increasing systemic steroids 2
• Steroid-sparing agents to allow continued systemic steroid reduction 1, 5
• Recent evidence supports dupilumab for refractory cases requiring steroid withdrawal 6

Common Pitfall to Avoid

Do not maintain the 25mg dose "to be safe" - the confusion represents active harm that will likely worsen with continued exposure. The risk of disease relapse is manageable and reversible; progressive steroid-induced cognitive impairment and its associated mortality risk in elderly patients is not.

The proposed taper is medically sound, guideline-concordant, and prioritizes the patient's immediate safety while maintaining reasonable disease control.